NRx Pharmaceuticals to Report First-Quarter Earnings on May 18
Analysts expect NRx Pharmaceuticals to post a loss of 11 cents per share on $19.43 million in revenue. The company recently received FDA clearance to begin a clinical trial of NRX-101. Several analysts maintained Buy ratings with price targets ranging from $25 to $49.
forbes.comNRx Pharmaceuticals, Inc. will release earnings for its first quarter before the opening bell on Monday, May 18. Analysts expect the company to report a quarterly loss of 11 cents per share. That compares with a loss of 34 cents per share in the year-ago period.
43 million, Benzinga reported. On May 7, NRx Pharma received clearance from the FDA to initiate a clinical trial of NRX-101 versus placebo in patients with depression and suicidality. The Wilmington, Delaware-based company trades under the ticker NRXP on NASDAQ.
21 on Thursday. 49 percent, in more recent trading. The article was published on May 15, 2026. Several analysts have maintained Buy ratings on the stock in recent weeks.
D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. Jason Kolbert has an accuracy rate of 47 percent, according to Benzinga.
Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on the same day.
BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. Thomas Shrader has an accuracy rate of 58 percent. Benzinga reported on the analyst actions ahead of the earnings release.
Key Facts
Story Timeline
6 events- 2026-05-15
Benzinga article published detailing upcoming earnings and analyst ratings
1 sourceBenzinga - 2026-05-07
NRx Pharma received FDA clearance for NRX-101 clinical trial
1 sourceBenzinga - 2026-05-05
D. Boral Capital's Jason Kolbert maintained Buy rating with $34 target
1 sourceBenzinga - 2026-04-27
Trucchio maintained Buy with $45 target; Ascendiant's Edward Woo raised target to $49
1 sourceBenzinga - 2026-03-24
BTIG's Thomas Shrader maintained Buy rating with $25 target
1 sourceBenzinga - 2026-05-18
NRx Pharmaceuticals scheduled to release Q1 earnings before market open
1 sourceBenzinga
Potential Impact
- 01
FDA trial clearance for NRX-101 may drive clinical development momentum in depression and suicidality treatment space
- 02
Quarterly loss narrowing from 34 cents to expected 11 cents could be viewed as operational progress
- 03
Positive analyst coverage with high price targets relative to current share price near $3.13 could support investor sentiment ahead of earnings
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…